ABNX.PA ABIONYX Pharma (EURONEXT) +26.33% after hours 30 Mar 2026: heavy volume

ABNX.PA stock led evening movers after hours, trading up 26.33% to €3.79 on EURONEXT on 30 Mar 2026. The move came on 652,212 shares, almost ten times average volume, and pushed the price above the 50-day average. Investors watched a sharp volume spike and a technical breakout. This article reviews the price action, valuation, technical setup, Meyka AI grade, and scenario-based forecasts for ABIONYX Pharma SA (ABNX.PA) in Europe.

Price action and after hours context for ABNX.PA stock

ABNX.PA rose 26.33% in after hours trade to €3.79, up €0.79 from the previous close of €3.00 on 30 Mar 2026. Intraday range was €3.67–€4.14 and volume hit 652,212 vs average 131,653, a relative volume of 10.43. Investing.com flagged ABNX among top gainers, which likely amplified retail interest source. The price now sits above its 50-day average of €3.54 and 200-day average of €3.10, signaling short-term strength.

Catalysts and news driving the ABNX.PA stock spike

No company press release matched the timing; market participants cited momentum from listings of top gainers and sector attention in biotech source. ABIONYX Pharma SA’s pipeline — including CER-001 and CER-002 development programs — keeps speculative flows active. The stock’s low float and recent positive sentiment in small-cap healthcare names can magnify share moves on limited news.

Valuation and fundamentals for ABNX.PA stock

ABIONYX trades at €3.79 with market cap €130,982,623 and EPS -0.13; trailing PE is negative at -28.58. Price-to-sales sits around 32.23 and price-to-book near 31.50, reflecting a biotech valuation mismatch to current revenue. Key ratios show a current ratio 1.06 and debt-to-equity 0.89, while R&D represents 36.86% of revenue. These metrics underline high research investment and negative profitability typical for development-stage biotechs.

Technical setup and trading signals for ABNX.PA stock

Momentum indicators show rising strength: RSI 63.34, ADX 33.38 (strong trend), MACD histogram positive. Bollinger bands middle at €3.28 with an upper band near €3.57, and on-balance volume is elevated. Price broke above short-term resistance near €3.50, supported by 50-day average €3.54. Traders should note ATR €0.21 and CCI 195.57, which point to overbought short-term conditions and higher intraday volatility.

Meyka AI grading and ABNX.PA stock outlook

Meyka AI rates ABNX.PA with a score out of 100: 65.03 / 100 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus. The model highlights balanced upside from pipeline progress but flags elevated valuation and negative earnings. These grades are informational only and not investment advice.

Forecasts, price targets and risk checklist for ABNX.PA stock

Meyka AI’s forecast model projects a quarterly target €4.42 and a 12-month target €5.87. At the current price €3.79, the 12-month target implies an upside of 54.88%. Conservative traders may use €4.42 as a near-term target and €10.44 as a bull-case three-year scenario. Key risks: negative EPS, high P/S and P/B multiples, clinical or trial delays, and liquidity-driven volatility. Upcoming calendar items include an earnings announcement on 2026-09-24, plus any clinical updates.

Final Thoughts

ABNX.PA stock’s after hours surge to €3.79 on 30 Mar 2026 reflects a classic small-cap biotech momentum move. Heavy volume of 652,212 shares and a break above the 50-day average signal short-term follow-through, but valuation remains stretched with negative EPS -0.13, P/S 32.23, and P/B 31.50. Meyka AI’s forecast model projects a 12-month target of €5.87, implying about 54.88% upside versus today’s price; forecasts are model-based projections and not guarantees. Given current metrics, our Meyka grade (B, 65.03/100) suggests a HOLD stance for risk-aware investors, with upside tied to pipeline progress and clinical milestones. Monitor liquidity, trial news, and the 2026-09-24 earnings date as decisive catalysts before repositioning a portfolio exposure to ABIONYX Pharma SA (ABNX.PA) on EURONEXT. For live market tools and the stock page, see Meyka AI’s coverage at Meyka stock page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.